What are the recommended dosing regimens for sodium bicarbonate (NaHCO₃) in adults and children for metabolic acidosis, hyperkalemia, and urinary alkalinization?

Sodium Bicarbonate Dosing

For pediatric patients with metabolic acidosis or hyperkalemia, administer 1-2 mEq/kg IV/IO slowly; for adults in cardiac arrest, give 50 mL (44.6-50 mEq) initially and repeat every 5-10 minutes as needed based on arterial blood gas monitoring. 1, 2

Pediatric Dosing

Acute Indications (Metabolic Acidosis, Hyperkalemia, Sodium Channel Blocker Overdose)

• Standard dose: 1-2 mEq/kg IV/IO given slowly 1
• Do NOT give by endotracheal route 1
• Newborn-specific requirement: Use only 0.5 mEq/mL concentration; dilution of stock solutions may be necessary 1

Critical precautions:

• Do not mix with vasoactive amines or calcium 1
• Effective ventilation must be established first—bicarbonate produces CO₂ that requires elimination 1
• Routine use in cardiac arrest is NOT recommended unless documented metabolic acidosis exists after adequate ventilation 1

Sodium Channel Blocker Overdose (Tricyclic Antidepressants)

• Initial bolus: 1-2 mEq/kg 1
• Target pH: 7.45-7.55 1
• Maintenance infusion: 150 mEq NaHCO₃/L solution to maintain alkalosis 1
• This indication has Class 1 (Level B-NR) evidence for adults and Class 2a (Level C-LD) for children 3

Adult Dosing

Cardiac Arrest

• Initial dose: 50 mL (44.6-50 mEq) rapid IV push 2
• Repeat: 50 mL every 5-10 minutes as indicated by arterial pH and blood gas monitoring 2
• Alternative initial dosing: 1-2 vials (44.6-100 mEq) 2

Important caveat: Bicarbonate solutions are hypertonic and may cause undesirable plasma sodium elevation. However, in cardiac arrest, acidosis risks exceed hypernatremia risks 2

Non-Emergent Metabolic Acidosis

• Dose: 2-5 mEq/kg over 4-8 hours 2
• Adjust based on severity (total CO₂ content, blood pH, clinical condition) 2
• Target: Total CO₂ ~20 mEq/L by end of first day (not full correction) 2

Critical pitfall: Attempting full correction within 24 hours risks unrecognized alkalosis due to delayed ventilatory readjustment 2. Achieving normal or above-normal total CO₂ on day 1 typically causes gross alkalosis with adverse effects 2.

Hyperkalemia in Cardiac Arrest

• Dose: 50 mL (44.6-50 mEq) IV push 3
• Class 2a recommendation (Level C-LD) based on animal data showing improved ROSC (92% vs 50%, OR 12.0, P=0.003) 3
• Shifts potassium intracellularly but does not eliminate it from the body 3, 4

Evidence strength: One randomized pig model showed significant benefit 3, but human retrospective data is limited and conflicting 3. Pediatric recommendations are extrapolated from adult data 3.

Urinary Alkalinization

Oral Dosing

• Adults: 4 g orally three times daily 5
• Achieves urine pH ≥7 by 10 hours and ≥8 by 20 hours 5
• FDA-approved OTC dosing: 1 tablet dissolved in water as needed 6
  • Maximum 24 tablets/day for adults <60 years
  • Maximum 12 tablets/day for adults ≥60 years
  • Not recommended for children 6

Special Populations and Contexts

Metabolic Acidosis in ICU Patients

Recent high-quality evidence from BICAR-ICU trial (n=389) showed:

• No benefit for primary composite outcome (death by day 28 + organ failure at day 7) in overall population 7
• Significant benefit in AKI subgroup (AKIN 2-3): 54% vs 37% survival at day 28 (P=0.0283) 7
• Chloride-dependent effects: Meta-analysis suggests benefit when chloride ≥113 mmol/L but harm when <107 mmol/L 8

Practical algorithm for ICU metabolic acidosis:

1. Check baseline chloride level
2. If chloride ≥113 mmol/L: Consider bicarbonate therapy
3. If chloride <107 mmol/L: Avoid bicarbonate (associated with increased mortality) 8
4. If moderate-severe AKI present: Consider therapy regardless of chloride if ≥113 mmol/L 7, 8

Pediatric Metabolic Acidosis

• Dose: 2-5 mEq/kg over 4-8 hours for less urgent situations 2
• Monitor with blood gases, plasma osmolarity, arterial lactate, hemodynamics 2
• Stepwise approach essential—response to given dose is not precisely predictable 2

Tumor Lysis Syndrome

Alkalinization is NOT routinely recommended 9

• No unequivocal evidence of efficacy 9
• May increase calcium phosphate crystal precipitation risk 9
• Only indicated for metabolic acidosis itself, not prophylactically 9

Monitoring Requirements

• Arterial blood gases for pH and PaCO₂ 2
• Serum electrolytes: Sodium, potassium, calcium 2
• Plasma osmolarity in shock-associated acidosis 2
• Glucose levels if co-administered with insulin 1

Common Adverse Effects

• Metabolic alkalosis (most common) 7
• Hypernatremia 7
• Hypocalcemia 7
• Volume overload from hypertonic solution 2

No life-threatening complications reported in major trials 7, but careful monitoring remains essential.

Key Clinical Pearls

1. Ventilation first, bicarbonate second: Adequate ventilation must be established before bicarbonate administration to eliminate generated CO₂ 1

2. Avoid over-correction: Target pH ~7.30, not full normalization, in first 24 hours 2

3. Chloride matters: In ICU patients, baseline chloride level predicts benefit vs harm 8

4. AKI changes the equation: Patients with moderate-severe AKI may benefit more from bicarbonate therapy 7

5. Cardiac arrest exception: In cardiac arrest, acidosis risks outweigh hypernatremia concerns—treat aggressively 2

6. Rebound hyperkalemia: For hyperkalemia, bicarbonate only provides temporary benefit (1-4 hours); initiate definitive potassium-lowering therapy early 10